Global Bacterial Partnering 2010-2017: Deal trends, players and financials
|発行||Current Partnering, a division of Wildwood Ventures Limited||商品コード||246682|
|細菌性感染症関連の各種提携契約：契約条件・合意内容 Global Bacterial Partnering 2010-2017: Deal trends, players and financials|
|出版日: 2017年09月01日||ページ情報: 英文||
The Global Bacterial Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.
‘Global Bacterial Partnering 2010 to 2017’ provides the full collection of Bacterial disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.
The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Bacterial dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Bacterial dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Bacterial deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Bacterial dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Bacterial deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Bacterial partnering deals by specific Bacterial target announced since 2010. The chapter is organized by specific Bacterial therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Bacterial partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Bacterial partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Bacterial technologies and products.
‘Global Bacterial Partnering 2010 to 2017’ is intended to provide the reader with an in-depth understanding and access to Bacterial trends and structure of deals entered into by leading companies worldwide.
‘Global Bacterial Partnering 2010 to 2017’ includes:
The report includes deals for the following indications:
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
In ‘Global Bacterial Partnering 2010 to 2017’, available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Bacterial Partnering 2010 to 2017’ report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals.
Analyzing actual contract agreements allows assessment of the following:
‘Global Bacterial Partnering 2010 to 2017’ provides the reader with the following key benefits: